Does ECULIZUMAB Cause Thrombotic microangiopathy? 636 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 636 reports of Thrombotic microangiopathy have been filed in association with ECULIZUMAB (SOLIRIS). This represents 1.4% of all adverse event reports for ECULIZUMAB.
636
Reports of Thrombotic microangiopathy with ECULIZUMAB
1.4%
of all ECULIZUMAB reports
133
Deaths
264
Hospitalizations
How Dangerous Is Thrombotic microangiopathy From ECULIZUMAB?
Of the 636 reports, 133 (20.9%) resulted in death, 264 (41.5%) required hospitalization, and 29 (4.6%) were considered life-threatening.
Is Thrombotic microangiopathy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ECULIZUMAB. However, 636 reports have been filed with the FAERS database.
What Other Side Effects Does ECULIZUMAB Cause?
Fatigue (4,858)
Off label use (4,228)
Haemoglobin decreased (3,028)
Headache (2,699)
Death (2,221)
Pyrexia (1,948)
Dyspnoea (1,819)
Asthenia (1,732)
Drug ineffective (1,644)
Nausea (1,579)
What Other Drugs Cause Thrombotic microangiopathy?
TACROLIMUS (1,982)
MYCOPHENOLATE MOFETIL (820)
CYCLOSPORINE (724)
GEMCITABINE (648)
CYCLOPHOSPHAMIDE (602)
FLUDARABINE (480)
METHOTREXATE (447)
CARFILZOMIB (350)
METHYLPREDNISOLONE (345)
MELPHALAN (332)
Which ECULIZUMAB Alternatives Have Lower Thrombotic microangiopathy Risk?
ECULIZUMAB vs EDARAVONE
ECULIZUMAB vs EDETATE
ECULIZUMAB vs EDOXABAN
ECULIZUMAB vs EDOXABAN TOSILATE
ECULIZUMAB vs EFALIZUMAB